Open Access

SLCO4A1, as a novel prognostic biomarker of non‑small cell lung cancer, promotes cell proliferation and migration

  • Authors:
    • Shihao Li
    • Zihao Li
    • Lan Huang
    • Zhenyang Geng
    • Feng Li
    • Bin Wu
    • Yinliang Sheng
    • Yifan Xu
    • Bowen Li
    • Yiming Xu
    • Zhuoyu Gu
    • Yu Qi
  • View Affiliations

  • Published online on: January 23, 2024     https://doi.org/10.3892/ijo.2024.5618
  • Article Number: 30
  • Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Solute carrier organic anion transporter family member 4A1 (SLCO4A1) is a membrane transporter protein. The role of this molecule in non‑small cell lung cancer (NSCLC) remains unclear. Bulk sequencing was carried out using early‑stage NSCLC tissues with lymph node metastasis to identify SLCO4A1 that influences NSCLC cell proliferation, metastasis and prognosis. The in vitro functional assays carried out included the following: Cell Counting Kit‑8, plate colony formation, Transwell and wound healing assays. The molecular techniques used included reverse transcription‑quantitative PCR, western blotting and immunohistochemistry. The present study revealed the role of SLCO4A in NSCLC. SLCO4A1 was found to be expressed at high levels in NSCLC tissues and cells, and promotes cell proliferation, migration and invasion. Kaplan‑Meier survival analysis indicated that patients with NSCLC and high expression of SLCO4A1 had a poor prognosis. SLCO4A was revealed to regulate the expression of the proliferation‑related proteins Ki‑67 and PCNA, and that of the extracellular matrix proteins vimentin and E‑cadherin. Mechanistically, SLCO4A1 may affect the MAPK signaling pathway to promote NSCLC cell proliferation, migration and invasion. In addition, bioinformatics analysis demonstrated a strong association between SLCO4A1 and tumor infiltrating immune cells, highlighting its critical role in immune therapies such as immune checkpoint inhibitor treatment of patients with NSCLC.
View Figures
View References

Related Articles

Journal Cover

March-2024
Volume 64 Issue 3

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Li S, Li Z, Huang L, Geng Z, Li F, Wu B, Sheng Y, Xu Y, Li B, Xu Y, Xu Y, et al: SLCO4A1, as a novel prognostic biomarker of non‑small cell lung cancer, promotes cell proliferation and migration. Int J Oncol 64: 30, 2024.
APA
Li, S., Li, Z., Huang, L., Geng, Z., Li, F., Wu, B. ... Qi, Y. (2024). SLCO4A1, as a novel prognostic biomarker of non‑small cell lung cancer, promotes cell proliferation and migration. International Journal of Oncology, 64, 30. https://doi.org/10.3892/ijo.2024.5618
MLA
Li, S., Li, Z., Huang, L., Geng, Z., Li, F., Wu, B., Sheng, Y., Xu, Y., Li, B., Xu, Y., Gu, Z., Qi, Y."SLCO4A1, as a novel prognostic biomarker of non‑small cell lung cancer, promotes cell proliferation and migration". International Journal of Oncology 64.3 (2024): 30.
Chicago
Li, S., Li, Z., Huang, L., Geng, Z., Li, F., Wu, B., Sheng, Y., Xu, Y., Li, B., Xu, Y., Gu, Z., Qi, Y."SLCO4A1, as a novel prognostic biomarker of non‑small cell lung cancer, promotes cell proliferation and migration". International Journal of Oncology 64, no. 3 (2024): 30. https://doi.org/10.3892/ijo.2024.5618